Back
ESC2025 Premium Access

Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial

Session: Cardiotoxicity and protection: from bench to bedside
Topic: Lipid-Lowering Agents
Speaker: Professor K. Parhofer (Munich, DE)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Professor Klaus G Parhofer

Ludwig Maximilians University, Munich (Germany)
5 presentations
2 followers

6 more presentations in this session

Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM

Speaker: Professor A. Wang (Durham, US)

Access
Abstract
Slides
Video
Like
Thumbnail

A UK multicentre experience of osimertinib related cardiovascular toxicity: real world patterns, risk stratification and surveillance

Speaker: Doctor C. Simela (London, GB)

Access
Abstract
Slides
Video
Like
Thumbnail

Impact of dapagliflozin on cardiac remodeling and sirtuin expression in rats with type 1 diabetes mellitus

Speaker: Associate Professor M. Okoshi (Botucatu, BR) Mrs A. Marreiros (Botucatu, BR)

Access
Abstract
Slides
Video
Like
Thumbnail

Maternal fluconazole use during the third trimester and risk of QT prolongation in the offspring

Speaker: Doctor G. Ninh (Herlev, DK)

Access
Abstract
Slides
Video
Like
Thumbnail

Ranolazine ameliorates palmitic acid-induced insulin resistance in HL-1 cardiomyocytes by Ca2+/ CaMKII modulation: an in vitro investigation and population-based cohort study

Speaker: Professor P. Liu (Tainan, TW)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Cardiotoxicity and protection: from bench to bedside

Speakers: Professor K. Parhofer, Professor A. Wang, Doctor C. Simela, Associate Professor M. Okoshi, Mrs A. Marreiros...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources